exclusive
Menarini Group and Insilico Medicine sign exclusive global license agreement for …
Florence, Italy and New York (ots/PRNewswire) KAT6 is a new target in hormone-sensitive breast cancer tumors and other cancers. Overexpression of KAT6A/B is associated with poor clinical outcomes in patients with ER+/HER2- breast cancer, one of the most common subtypes. The molecule showed high preclinical activity. Insilico presented data on this new molecule at the […]
Menarini Group and Insilico Medicine sign exclusive global license agreement for …
Florence, Italy and New York (ots/PRNewswire) KAT6 is a new target in hormone-sensitive breast cancer tumors and other cancers. Overexpression of KAT6A/B is associated with poor clinical outcomes in patients with ER+/HER2- breast cancer, one of the most common subtypes. The molecule showed high preclinical activity. Insilico presented data on this new molecule at the […]
Menarini Group and Insilico Medicine enter into exclusive global license agreement for new KAT6 inhibitor for potential treatment of breast cancer and other oncology indications USA – Deutsch Italia – Italiano APAC – Traditional Chinese USA – español Latin America – español USA – English USA – English
KAT6 is a new target in hormone-sensitive breast cancer tumors and other cancers. Overexpression of KAT6A/B is associated with poor clinical outcomes in patients with ER+/HER2- breast cancer, one of the most common subtypes. The molecule showed high preclinical activity. Insilico presented data on this new molecule at the San Antonio Breast Cancer Symposium in […]